Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Associated Therapies: -

Clinical Trials

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: pazopanib
Drug: sunitinib

First Posted Date: 2010-02-08

Last Posted Date: 2017-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 169

Registration Number: NCT01064310

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Non Small Cell Lung Cancer
Metastatic Breast Cancer

Interventions: Drug: Pazopanib
Drug: Vinorelbine

First Posted Date: 2010-02-02

Last Posted Date: 2013-10-30

Lead Sponsor: Northwestern University

Target Recruit Count: 8

Registration Number: NCT01060514

Locations: 🇺🇸
Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States

Phase II Pazopanib Study in Advanced Dermatofibrosarcomas

Phase 2

Terminated

Conditions: Dermatofibrosarcomas of DARIER FERRAND(DFSP)

Interventions: Drug: Pazopanib

First Posted Date: 2010-02-01

Last Posted Date: 2016-07-01

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 23

Registration Number: NCT01059656

Locations: 🇫🇷
Hôpital Saint-Louis - Service de Dermatologie (Pole POPS), Paris, France

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Carcinoma

Interventions: Drug: Pazopanib
Drug: Doxil

First Posted Date: 2009-12-21

Last Posted Date: 2021-10-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 22

Registration Number: NCT01035658

Locations: 🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 1 locations

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pazopanib
Drug: Erlotinib

First Posted Date: 2009-12-08

Last Posted Date: 2016-01-29

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 202

Registration Number: NCT01027598

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 5 locations

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Breast Cancer
Lung Cancer
Colon Cancer
Pancreatic Cancer
Head and Neck Cancer
Kidney Cancer
Sarcoma
Hepatocellular Cancer

Interventions: Drug: Pazopanib
Drug: Ixabepilone

First Posted Date: 2009-11-13

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 31

Registration Number: NCT01012362

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Placebo
Drug: Pazopanib

First Posted Date: 2009-03-20

Last Posted Date: 2021-02-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 940

Registration Number: NCT00866697

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pazopanib
Drug: paclitaxel

First Posted Date: 2009-03-20

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00866528

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

VEG111485: A QTc Study of Pazopanib

Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Other: Placebo for pazopanib
Drug: Pazopanib
Drug: Moxifloxacin
Other: Placebo for moxifloxacin

First Posted Date: 2009-03-13

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2

Registration Number: NCT00861029

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Phase 2

Completed

Conditions: Lymphedema

Interventions: Drug: Pazopanib

First Posted Date: 2009-01-22

Last Posted Date: 2023-10-16

Lead Sponsor: Kathy Miller

Target Recruit Count: 10

Registration Number: NCT00827372

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy